RecruitingNCT07314164
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Studying Germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (28)
- Medizinische Universitaet Graz, Graz, Austria
- Kepler Universitaetsklinikum GmbH Linz, Linz, Austria
- MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany
- DRK Kliniken Berlin, Berlin, Germany
- Evangelische Lungenklinik Berlin, Berlin, Germany
- Krankenhaus St. Joseph-Stift Bremen GmbH, Bremen, Germany
- Klinikum Chemnitz, Chemnitz, Germany
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring, Cologne, Germany
- pioh Studien und Mangement GbR, Cologne, Germany
- Gemeinschaftspraxis Haematologie - Onkologie, Dresden, Germany
- Technische Univiersitaet (TU) Dresden, Dresden, Germany
- Universitaetsklinikum Essen, Essen, Germany
- Krankenhaus Nordwest, Frankfurt, Germany
- Uniklinikum Frankfurt, Frankfurt am Main, Germany
- Universitaetsklinikum Giessen-Marburg, Giesen, Germany
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07314164 on ClinicalTrials.govOther trials for Germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552233NK Cell Therapy for Malignant Solid Brain TumorsPeking University Third Hospital
- RECRUITINGPHASE1NCT07143812A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed GlioblastomaCHA University
- RECRUITINGNANCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD.
- RECRUITINGNANCT07459101UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4Sunnybrook Health Sciences Centre
- RECRUITINGPHASE1, PHASE2NCT07193966NG2 and DLL3 CAR-T Cells Targeting MelanomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford University
- RECRUITINGPHASE1, PHASE2NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasAnn & Robert H Lurie Children's Hospital of Chicago
- RECRUITINGPHASE1, PHASE2NCT06440057Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.Suzhou Zelgen Biopharmaceuticals Co.,Ltd